RESEARCH / DISCOVERY
← Back to the library

[Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].

[Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].

Read the original publication

A plain-language reading has not been prepared for this paper yet.

Original abstract

On the basis of a reassessment of the aetiopathogenetic problem and the neuroendocrine implications, the therapeutic effectiveness of a prolactin inhibitor, 2-alpha-Br-ergocryptine (CB 154), in Parkinson's disease is assessed. Five patients were treated for a total of two weeks using doses between 10 and 15 mg/die. CB 154 was found to act as a dopaminergic receptor agonist at nigro-striatal level, considerably improving tremor and rigidity and to a lesser extent bradykinesia and total disability.

Explore another example or bring your own paper

Pasted text and PDF extraction stay on this computer. The local guide explains terms and surfaces passages; rewriting requires a configured local model. Scanned PDFs need OCR first.

RECORD & PROVENANCE